1 active not recruiting, 1 completed, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow Casdozokitug: new trials by email Literature Review of Casdozokitug trials Research Report on Casdozokitug
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma Casdozokitug, Toripalimab, Bevacizumab - Hepatocellular Carcinoma | Phase 2 | Active not recruiting | Coherus Oncology, Inc. | 72 | 2024-12-20 | 2026-07-15 |
| Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma Casdozokitug, Atezolizumab, Bevacizumab - Hepatocellular Carcinoma | Phase 2 | Terminated | Coherus Oncology, Inc. | 30 | 2022-04-12 | 2026-10-01 |
| Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors CHS-388, Pembrolizumab, Toripalimab - Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma | Phase 1 | Completed | Coherus Oncology, Inc. | 145 | 2020-04-22 | 2026-07-15 |
Carcinoma, Hepatocellular (3) · Liver Neoplasms (3) · Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Kidney Neoplasms (1)
United States (3) · Australia (2) · Singapore (2) · South Korea (2) · Taiwan (2) · Canada (1) · Hong Kong (1)